Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation Meeting Abstract
| Authors: | Zhu, A. X.; Macarulla, T.; Javle, M. M.; Kelley, R. K.; Lubner, S. J.; Adeva, J.; Cleary, J. M.; Catenacci, D. V. T.; Borad, M. J.; Bridgewater, J. A.; Harris, W. P.; Murphy, A. G.; Oh, D. Y.; Whisenant, J. R.; Wu, B.; Jiang, L.; Gliser, C.; Pandya, S. S.; Valle, J. W.; Abou-Alfa, G. K. |
| Abstract Title: | Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation |
| Meeting Title: | 2021 Gastrointestinal Cancers Symposium (ASCO GI) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 15-17 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-01-20 |
| Language: | English |
| ACCESSION: | WOS:000636712800283 |
| DOI: | 10.1200/JCO.2021.39.3_suppl.266 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 266 -- Source: Wos |
